Advertisement
Screener

BIO-TECHNE Corp (TECH) Finite-lived Intangible Assets Acquired

2.8 / 5 stars · 68/120 Roast Me

BIO-TECHNE Corp Finite-lived Intangible Assets Acquired

BIO-TECHNE Corp (TECH) reported Finite-lived Intangible Assets Acquired of $66.40 million for the 12-month period ending 2024-06-30, per its 10-K filed 2025-08-22.

Financial Statements › Notes › Goodwill and Other

us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2025-08-22

  • BIO-TECHNE Corp finite-lived intangible assets acquired for the quarter ending 2024-06-30 was $0.00.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for the quarter ending 2024-03-31 was $0.00.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for the quarter ending 2023-12-31 was $0.00.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for the quarter ending 2023-09-30 was $66.40M, a 12.17% decline year-over-year.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for fiscal 2024 was $66.40M, a 12.17% decline from fiscal 2023.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for fiscal 2023 was $75.60M.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for fiscal 2021 was $153.31M.
  • BIO-TECHNE Corp finite-lived intangible assets acquired for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
Period endFinite-lived Intangible Assets Acquired 3 monthFinite-lived Intangible Assets Acquired 6 monthFinite-lived Intangible Assets Acquired 9 monthFinite-lived Intangible Assets Acquired 12 month
2024-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22
$0.00
derived: sum of 2 quarters · filed 2025-08-22
$0.00
derived: sum of 3 quarters · filed 2025-08-22
$66.40M
10-K · filed 2025-08-22
2024-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06
$0.00
derived: sum of 2 quarters · filed 2024-05-06
$66.40M
10-Q · filed 2024-05-06
$66.40M
derived: sum of 4 quarters · filed 2024-08-22
2023-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07
$66.40M
10-Q · filed 2024-02-07
$66.40M
derived: sum of 3 quarters · filed 2024-08-22
$66.40M
derived: sum of 4 quarters · filed 2024-08-22
2023-09-30$66.40M
10-Q · filed 2023-11-07
$66.40M
derived: sum of 2 quarters · filed 2024-08-22
$66.40M
derived: sum of 3 quarters · filed 2024-08-22
$66.40M
derived: sum of 4 quarters · filed 2024-08-22
2023-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22
$0.00
derived: sum of 2 quarters · filed 2024-08-22
$0.00
derived: sum of 3 quarters · filed 2024-08-22
$75.60M
10-K · filed 2024-08-22
2023-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08
$0.00
derived: sum of 2 quarters · filed 2023-05-08
$75.60M
10-Q · filed 2023-05-08
2022-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07
$75.60M
10-Q · filed 2023-02-07
2022-09-30$75.60M
10-Q · filed 2022-11-07
2021-12-31$0.00
10-Q · filed 2022-02-07
$0.00
derived: sum of 2 quarters · filed 2022-02-07
$144.39M
derived: sum of 3 quarters · filed 2022-08-24
$144.39M
derived: sum of 4 quarters · filed 2022-08-24
2021-09-30$0.00
10-Q · filed 2021-11-08
$144.39M
derived: sum of 2 quarters · filed 2022-08-24
$144.39M
derived: sum of 3 quarters · filed 2022-08-24
$153.31M
derived: sum of 4 quarters · filed 2022-08-24
2021-06-30$144.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24
$144.39M
derived: sum of 2 quarters · filed 2022-08-24
$153.31M
derived: sum of 3 quarters · filed 2022-08-24
$153.31M
10-K · filed 2022-08-24
2021-03-31-$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-07
$8.92M
derived: sum of 2 quarters · filed 2021-05-07
$8.92M
10-Q · filed 2021-05-07
$8.92M
derived: sum of 4 quarters · filed 2021-08-25
2020-12-31$8.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-08
$8.92M
10-Q · filed 2021-02-08
$8.92M
derived: sum of 3 quarters · filed 2021-08-25
$8.92M
derived: sum of 4 quarters · filed 2021-08-25
2020-09-30$0.00
10-Q · filed 2020-11-09
$0.00
derived: sum of 2 quarters · filed 2021-08-25
$0.00
derived: sum of 3 quarters · filed 2021-08-25
$0.00
derived: sum of 4 quarters · filed 2021-08-25
2020-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25
$0.00
derived: sum of 2 quarters · filed 2021-08-25
$0.00
derived: sum of 3 quarters · filed 2021-08-25
$0.00
10-K · filed 2021-08-25
2020-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11
$0.00
derived: sum of 2 quarters · filed 2020-05-11
$0.00
10-Q · filed 2020-05-11
$14.46M
derived: sum of 4 quarters · filed 2020-08-26
2019-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06
$0.00
10-Q · filed 2020-02-06
$14.46M
derived: sum of 3 quarters · filed 2020-08-26
-$1.44M
derived: sum of 4 quarters · filed 2020-08-26
2019-09-30$0.00
10-Q · filed 2019-11-06
$14.46M
derived: sum of 2 quarters · filed 2020-08-26
-$1.44M
derived: sum of 3 quarters · filed 2020-08-26
-$8.04M
derived: sum of 4 quarters · filed 2020-08-26
2019-06-30$14.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26
-$1.44M
derived: sum of 2 quarters · filed 2020-08-26
-$8.04M
derived: sum of 3 quarters · filed 2020-08-26
$191.96M
10-K · filed 2020-08-26
2019-03-31-$15.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-07
-$22.50M
derived: sum of 2 quarters · filed 2019-05-07
$177.50M
10-Q · filed 2019-05-07
$194.88M
derived: sum of 4 quarters · filed 2019-11-06
2018-12-31-$6.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07
$193.40M
10-Q · filed 2019-02-07
$210.78M
derived: sum of 3 quarters · filed 2019-11-06
$228.55M
derived: sum of 4 quarters · filed 2019-11-06
2018-09-30$200.00M
10-Q · filed 2018-11-07
$217.38M
derived: sum of 2 quarters · filed 2019-11-06
$235.15M
derived: sum of 3 quarters · filed 2019-11-06
$233.57M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30$17.38M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06
$35.15M
derived: sum of 2 quarters · filed 2019-11-06
$33.57M
derived: sum of 3 quarters · filed 2019-11-06
$40.67M
10-K/A · filed 2019-11-06
2018-03-31$17.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09
$16.19M
derived: sum of 2 quarters · filed 2018-05-09
$23.29M
10-Q · filed 2018-05-09
$292.00K
derived: sum of 4 quarters · filed 2018-08-27
2017-12-31-$1.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08
$5.52M
10-Q · filed 2018-02-08
-$17.48M
derived: sum of 3 quarters · filed 2018-08-27
-$17.48M
derived: sum of 4 quarters · filed 2018-08-27
2017-09-30$7.10M
10-Q · filed 2017-11-09
-$15.90M
derived: sum of 2 quarters · filed 2018-08-27
-$15.90M
derived: sum of 3 quarters · filed 2018-08-27
-$14.80M
derived: sum of 4 quarters · filed 2018-08-27
2017-06-30-$23.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27
-$23.00M
derived: sum of 2 quarters · filed 2018-08-27
-$21.90M
derived: sum of 3 quarters · filed 2018-08-27
$185.87M
10-K · filed 2018-08-27
2017-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10
$1.10M
derived: sum of 2 quarters · filed 2017-05-10
$208.87M
10-Q · filed 2017-05-10
$213.54M
derived: sum of 4 quarters · filed 2017-09-07
2016-12-31$1.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09
$208.87M
10-Q · filed 2017-02-09
$213.54M
derived: sum of 3 quarters · filed 2017-09-07
$216.04M
derived: sum of 4 quarters · filed 2017-09-07
2016-09-30$207.77M
10-Q · filed 2016-11-09
$212.44M
derived: sum of 2 quarters · filed 2017-09-07
$214.94M
derived: sum of 3 quarters · filed 2017-09-07
$215.17M
derived: sum of 4 quarters · filed 2017-09-07
2016-06-30$4.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07
$7.17M
derived: sum of 2 quarters · filed 2017-09-07
$7.40M
derived: sum of 3 quarters · filed 2017-09-07
$53.50M
10-K · filed 2017-09-07
2016-03-31$2.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10
$2.73M
derived: sum of 2 quarters · filed 2016-05-10
$48.83M
10-Q · filed 2016-05-10
$48.52M
derived: sum of 4 quarters · filed 2016-08-29
2015-12-31$225.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09
$46.33M
10-Q · filed 2016-02-09
$46.02M
derived: sum of 3 quarters · filed 2016-08-29
$44.33M
derived: sum of 4 quarters · filed 2016-08-29
2015-09-30$46.10M
10-Q · filed 2015-11-09
$45.80M
derived: sum of 2 quarters · filed 2016-08-29
$44.10M
derived: sum of 3 quarters · filed 2016-08-29
$63.00M
derived: sum of 4 quarters · filed 2016-08-29
2015-06-30-$300.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29
-$2.00M
derived: sum of 2 quarters · filed 2016-08-29
$16.90M
derived: sum of 3 quarters · filed 2016-08-29
$222.71M
10-K · filed 2016-08-29
2015-03-31-$1.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11
$17.20M
derived: sum of 2 quarters · filed 2015-05-11
$223.01M
10-Q · filed 2015-05-11
$237.63M
derived: sum of 4 quarters · filed 2015-08-31
2014-12-31$18.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09
$224.71M
10-Q · filed 2015-02-09
$239.33M
derived: sum of 3 quarters · filed 2015-08-31
$239.33M
derived: sum of 4 quarters · filed 2015-08-31
2014-09-30$205.81M
10-Q · filed 2014-11-10
$220.43M
derived: sum of 2 quarters · filed 2015-08-31
$220.43M
derived: sum of 3 quarters · filed 2015-08-31
$220.43M
derived: sum of 4 quarters · filed 2015-08-31
2014-06-30$14.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31
$14.62M
derived: sum of 2 quarters · filed 2015-08-31
$14.62M
derived: sum of 3 quarters · filed 2015-08-31
$75.12M
10-K · filed 2015-08-31
2014-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12
$0.00
derived: sum of 2 quarters · filed 2014-05-12
$60.50M
10-Q · filed 2014-05-12
2013-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-04
$60.50M
10-Q · filed 2014-02-04
2013-09-30$60.50M
10-Q · filed 2013-11-12
2013-06-30$0.00
10-K · filed 2014-08-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Twist Bioscience Corp (TWST)United States$11.540B-47.21
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78